May 17, 2023 / 12:00PM GMT
Paul J. Sekhri - Pharming Group N.V. - Independent Non-Executive Chairman
Good afternoon, ladies and gentlemen. I'm Paul Sekhri, Chairman of the Board of Directors. And as such, I would like to welcome you all to this Annual General Meeting of Shareholders of Pharming Group N.V. I would also like to welcome our shareholders who are following this meeting through the live webcast. This year marks the 35th year anniversary in which Pharming has been on the market. And while this is surely something to be celebrated, I'd also like to say that this is a very important year in our company's history for many other reasons as well. On March 24, we proudly announced that the U.S. Food and Drug Administration has granted approval of leniolisib for APDS. For those of you who don't know what that is, it's activated PI3 kinase delta syndrome. I'll just refer to it as APDS.
Approximately 2 weeks after approval, the first shipments of Joenja, the brand name used for leniolisib, for APDS, were delivered to patients in the U.S. The U.S. launch of Joenja is an important milestone for people in the U.S. living with
Pharming Group NV Annual Shareholders Meeting Transcript
May 17, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers